Hello, my name is Dr. Joshua Richter. I'm an associate professor of medicine at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, and the director of myeloma at the Blobotnik Family Chelsea Medical Center at Mount Sinai here at EHA 2024. So in the world of bispecific antibodies, I think everyone has come to know the BCMA CD3 bispecific antibodies like teclistomab and l-rinatumab, and the GPRC5D bispecific antibodies like talcretumab. Sevastomab targets a different antigen called FCRH5, and FCRH5 is ubiquitously expressed on all plasma cells, not having some of the same degree of infectious complications that we're seeing with some of the BCMA drugs, but also not having that off-target skin and dysquisiotoxicity that we see with the GPRC5D bispecifics. One of the most exciting presentations this year is going to be given by Shaji Kumar. I'm somewhere in the middle of the authorship, but really excited about the data that we're putting forward from Sevastomab, from the KAMA2 trial. And if we've looked across the congresses over the last two years, it's been the BCMA story and the GPRC5D story. But unfortunately, we're having patients progressing beyond BCMA-based therapies, and we're looking for the next generation of treatments. The KAMA2 protocol is specifically looking at patients progressing beyond BCMA-based therapies, and this is some of the first data from the KAMA2 study, looking at patients progressing beyond BCMA-based ADCs like Bilanetomab and beyond BCMA-based CAR T cell therapy like CAR-VICTi and IDA cell. Presenting the overall cohort has around a 67% overall response rate, which is about 60% post-ADC and 73% post-CAR T. And in the CAR T subgroup, 55% of patients had a VGPR or better. So as we're struggling to find the pathway to cure, right now CAR T is provided as some of the longest duration of therapy and treatment and progression-free survival and overall survival, amazing data. But unfortunately, patients are still progressing. And with this data being presented for KAMA2, looking at a 73% response rate in this patient cohort, we're really excited for the future approval of a drug like this to use in those patients.
HealthTree • June 21, 2024